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Abstract
Background: Thalassemic patients suffer from diabetes mellitus secondary to hemosiderosis.
Aims: The study aimed to evaluate pancreatic iron overload by T2*-weighted Gradient-echo magnetic resonance 
imaging (MRI) in young beta-thalassemia major patients and to correlate it with glucose disturbances, hepatic 
hemosiderosis, serum ferritin and splenectomy.
Methods: Forty thalassemic patients (20 non diabetic, 10 diabetic, and 10 with impaired glucose tolerance) were 
recruited from Pediatric Hematology Clinic, in addition to 20 healthy controls. All patients underwent clinical 
assessment and laboratory investigations included complete blood count, liver function tests, serum ferritin and oral 
glucose tolerance test (OGTT). A T2*-weighted gradient-echo sequence MRI was performed with 1.5 T scanner and 
signal intensity ratio (SIR) of the liver and the pancreas to noise were calculated.
Results: Significant reduction in signal intensity ratio (SIR) of the liver and the pancreas was shown in thalassemic 
patients compared to controls (P < 0.0001), Thalassemic patients with abnormal glucose tolerance; including diabetics 
and thalassemics with impaired glucose tolerance; displayed a higher degree of pancreatic and hepatic siderosis 
compared to thalassemics with normal glucose tolerance or controls (P < 0.001, P < 0.0001). Splenectomized 
thalassemic patients had significantly lower SIR of pancreas compared to non splenectomized patients (P < 0.05). A 
strong correlation was present between hepatic and pancreatic siderosis in studied patients (P < 0.001).
Conclusions: pancreatic siderosis can be detected by T2* gradient-echo MRI since childhood in thalassemic patients, 
and is more evident in patients with abnormal glucose tolerance. After splenectomy, iron deposition may be 
accelerated in the pancreas. Follow up of thalassemic patients using pancreatic MRI together with intensive chelation 
therapy may help to prevent the development of overt diabetes.
Introduction
Thalassemic patients affected by systemic iron overload,
often die owing to iron induced failure of vital organs
such as heart and liver. Impairment of the endocrine and
exocrine function of the pancreas is a common complica-
tion in patients with beta-thalassemia major [1,2]. The
incidence of impaired glucose tolerance and diabetes in
thalassemia major patients varied from 9% to 15%
depending on the age of assessment, the intensity of
chelation, transfusion and related patient compliance
[ 3 , 4 ] .  T h e  e t i o l o g y  o f  d i a b e t e s  i n  β - t h a l a s s e m i a  i s
increased peripheral resistance to insulin and direct toxic
effect of excess iron in the acinar and beta cells of pan-
creas resulting in insulin deficiency [5]. Structural abnor-
malities of the pancreas have been described on
sonography [1,6].
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Magnetic resonance imaging has emerged for the non-
invasive quantification of hepatic iron [7,8]; it represents
a reliable method for assessing iron overload in various
tissues, not easily accessible with other techniques [9,10].
Despite extensive research on MRI of hepatic and cardiac
iron overload, there have been limited data on the MRI of
pancreas in patients with β-thalassemia major [11-13].
Moreover, the relation between pancreatic and hepatic
siderosis and, between MRI of the pancreas and diabetes
has not been documented in medical literature [13]. Very
few studies have evaluated the effect of age on pancreatic
siderosis and compared MRI data from younger and
older patients with thalassemia [12].
The objective of this study was to evaluate pancreatic
iron overload by the non-invasive T2*-weighted gradient-
echo MRI (T2*GRE) in children and adolescents with
beta thalassemia major and to correlate it with glucose
disturbances, splenectomy, serum ferritin, and hepatic
siderosis as expressed by signal intensity ratio.
Subjects and Methods
This cross-sectional study comprised 40 Egyptian trans-
fusion dependant β-thalassemia major patients (24 males
and 16 females) recruited from the Hematology Clinic,
Children's Hospital, Ain Shams University, Cairo, Egypt.
The study was approved by the Local Ethical Committee.
All patients were diagnosed as β-thalassemia major based
on clinical and hematological evaluation, age ranged
between 8-18 years (13.58 ± 3.57). Patients were clinically
evaluated. All patients were on regular blood transfusion
(15 ml packed RBCs/Kg body weight) at 2-4 weeks inter-
val to keep their hemoglobin at a level of 6-8 g/dl before
each transfusion. Patients were receiving chelation ther-
apy with subcutaneous deferoxamine mesylate (Desferal,
Ciba Geigy, Basel, Switzerland) (30 to 40 mg/kg per day)
or oral Deferiprone (50-75 mg/kg/day). Compliance to
chelation therapy varied among patients from two to five
days per week. Those having acute systemic infection
w e r e  t e m por arily e x c l uded fr o m  t he  s t udy t o o m it  t he
influence of infection on ferritin. Splenectomy has been
performed in 32/40 patients (80%). The studied patients
were categorized according to the results of OGTT into
20 patients with thalassemia major with normal glucose
tolerance (NGT) and 20 patients with abnormal glucose
tolerance. Those with abnormal glucose tolerance were
further subdivided into 10 patients with impaired glucose
tolerance (IGT) and 10 patients with overt diabetes (8
were known diabetics on insulin therapy and 2 were diag-
nosed during the study by OGTT). Their data are shown
in (Table 1). Twenty age and sex matched healthy chil-
dren and adolescents, 12 males and 8 females; aged 13.6 ±
2.39 years with normal hemogram, liver function tests,
serum ferritin and OGTT served as control group.
Informed consent was obtained before the study from all
subjects or their legal guardians.
Laboratory investigations: Complete blood count was
performed using coulter B66, Miami, Florida, USA,
serum ferritin on immulite instrument (Diagnostic prod-
ucts corporation 5700 West 96 St. Los Angeles, USA),
fasting blood glucose(FBG), postprandial blood glucose
(PP), liver function tests including aspartate aminotrans-
ferase (AST), alanine aminotransferase (ALT) using Syn-
chron CX9 autoanalyzer (Brea, California, USA). Oral
glucose tolerance test (OGTT) was performed as
described by WHO [14], using a glucose load containing
the equivalent of 1.75 g/kg body weight to a maximum of
75 g anhydrous glucose dissolved in water. For evaluation
of OGTT test, WHO criteria were used: (normal glucose
tolerance: venous plasma glucose 2 hours after glucose
load <140 mg/dl; impaired glucose tolerance: 140-199
mg/dl; diabetes mellitus: ≥200 mg/dl). Diagnosis of diabe-
tes mellitus was also considered when fasting plasma glu-
cose was ≥126 mg/dl on at least two occasions [14].
T2*MRI imaging
Technique
All MRI examinations were performed with a 1.5 T scan-
ner (Gyroscan ACS NT; Philips Medical Systems, Best,
the Netherlands). Breath-hold gradient-echo sequence
was performed using a body coil to avoid signal drop-off
[15] and to ensure the highest uniformity in the signal-to-
noise ratio throughout the scanned volume. The pulse
sequence applied was T2-weighted gradient-echo
sequence TR/TE = 120/15 msec with 25 slices to cover
the whole abdomen, including the liver and pancreas in
the scanning field. The patients were laid supine on the
scanner table. It was obtained in the axial plane, flip angle
20°; with slice thickness 7 mm with an interslice gap of 1
mm, image matrix 256 × 256 pixels and a field of view of
370 (350-400 mm). These MRI protocol was based on lit-
erature data[15,16].
Image interpretation
The signals intensity (SI) of the hepatic parenchyma was
considered as the average of three signals intensity mea-
surements obtained at circular regions of interest (ROIs)
that measured 1-2 cm2, always greater than 35 pixels and
were located in the right lobe of liver, away from vascular
structures or breathing artifacts and far from organ
boundaries. We measured the signal intensity of the pan-
creatic parenchyma in two ROIs measuring 1-2 cm2 far
from the boundaries of the organ to avoid apparent blood
vessels and bile ducts and estimated the average. Signal to
noise ratio was calculated.Matter et al. Diabetology & Metabolic Syndrome 2010, 2:23
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Statistical Analysis
Analysis of data was performed using SPSS (version 15).
Comparison between 2 groups of patients was made
using Student's t-test for parametric measures and Mann-
Whitney U test for non parametric measures. Compari-
son between multiple groups of patients was made using
ANOVA test and Kruskal-Wallis test. Differences in pro-
portions between 2 groups were evaluated using Chi-
Square test and Fisher's exact test. Spearman's rank cor-
relation coefficient was used to measure how SIR and
other parameters were correlated. P value < 0.05 was con-
sidered the cut-off value for significance.
Results
Thalassemic patients with NGT and abnormal glucose
tolerance were comparable as regards mean age, age at
diagnosis, duration of disease, Hb% and liver enzymes (P
> 0.05). There were significantly higher mean fasting
blood glucose (FBG), postprandial blood glucose (PP)
and mean serum ferritin levels in patients with abnormal
glucose tolerance compared to non diabetic patients (P <
0.05) (Table 2). The two patient groups were also compa-
rable as regards the distribution of sex and splenectomy
using Fisher's exact test (P > 0.05).
Siderosis was detected on the basis of decreased signal
in T2* GRE sequence to less than mean value ± 2 SD of
normal controls (Figures 1, 2). Hepatic siderosis was diag-
nosed in 36/40 (90%) of thalassemic patients and pancre-
atic siderosis in 34/40 (85%) of patients. Siderosis was
detected as early as the age of 8 years. The mean SIR of
the liver and the pancreas were significantly reduced in
different groups of patients compared to controls (P <
0.0001) (Table 3, Figure 3). Thalassemic patients with
abnormal glucose tolerance showed significant reduction
Table 1: Clinical and laboratory data of thalassemic patients with normal glucose tolerance, impaired glucose tolerance 
and diabetes.
Parameters Normal Glucose 
Tolerance(20)
Impaired Glucose Tolerance (10) Diabetics (10)
Male/Female 14/6 5/5 6/4
Mean ± SD Mean ± SD Mean ± SD
Age (yrs) 13.15 ± 3.56 14.80 ± 3.12 14.90 ± 2.69
Age of diagnosis (ms) 8.5 ± 6.53 7.80 ± 3.22 6.70 ± 2.50
Duration of disease(yrs) 12.42 ± 3.52 13.21 ± 3.3 14.34 ± 2.66
Duration of chelation (yrs) 5.80 ± 3.07 5.55 ± 4.31 5.90 ± 2.96
Hb (g/dL) 7.46 ± 1.24 7.53 ± 1.23 7.39 ± 0.86
AST (IU/L) 64.80 ± 44.06 86.89 ± 40.07 74.80 ± 41.52
ALT (IU/L) 66.40 ± 53.74 107.50 ± 84.53 67.70 ± 27.77
Serum ferritin (ng/ml) 1999.90 ± 932.95 3223.60 ± 2188.23 3438 ± 1327.60
FBG (mg/dL) 82.40 ± 7.16 107.8 ± 16.4 145.30 ± 29.50
PP (mg/dL) 120.80 ± 9.55 175.2 ± 17.9 236.80 ± 29.81
Frequency of blood 
transfusion (wk interval)
3.05 ± 0.6 3.2 ± 0.63 3.4 ± 0.84
SD, standard deviation; Hb, Hemoglobin; AST, aspartate aminotransferase; ALT, alanine aminotransferase; FBG, fasting blood glucose; PP, 
postprandial blood glucoseMatter et al. Diabetology & Metabolic Syndrome 2010, 2:23
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in SIR of the liver and the pancreas compared to those
with NGT (P < 0.0001) with no significant difference
between diabetics and IGT patients (P > 0.05). Spear-
man's correlation coefficient revealed that both SIR of
pancreas and liver were correlated together (P < 0.001)
and with age at diagnosis (P < 0.001, P < 0.01 respec-
tively). Both hepatic and pancreatic SIR showed a nega-
tive correlation with liver enzymes, blood glucose and
serum ferritin (P < 0.05) (Table 4).
Splenectomized thalassemic patients showed signifi-
cant reduction in SIR of the pancreas compared to non
splenectomized patients (P < 0.05) although insignificant
difference was shown between both groups as regards
age, duration of disease, serum ferritin, frequency of
blood transfusion and SIR of the liver (P > 0.05) (Table 5).
Discussion
The prevalence of IGT and diabetes in thalassemia major
patients varied from 8% up to 27% [5,17-20] in various
studies. Higher serum ferritin level in our patients with
abnormal glucose tolerance compared to patients with
NGT is in agreement with others [20]. Serum ferritin is
considered as a risk factor for abnormal glucose tolerance
in beta thalassemia patients [21]. Long term iron balance,
rather than current iron status, is related to the develop-
ment of glucose intolerance [22]. More compliant
patients to chelation were encountered in the thalassemic
group with NGT compared to the abnormal glucose tol-
erance group in our study.
Liver to noise ratio has been proposed to serve as a ref-
erence to quantify significant iron overload at 1.5 T [16].
The liver to noise ratio was slightly better correlated to
liver iron concentration than was the liver to muscle ratio
[23]. Gradient-echo sequences are particularly sensitive
to iron deposition because of the lack of the 180° refocus-
ing pulse that partially recovers signal loss from the field
inhomogeneity in spin-echo images [24]. In the current
study, the single breath T2* gradient-echo sequence was
also preferred for its short scanning time making it more
convenient in young age.
In the present study, there is significantly lower SIR of
the liver and the pancreas in thalassemic patients com-
pared to controls; the diagnosis of hepatic siderosis was
posed in 36/40 patients (90%) and of pancreatic siderosis
in 34/40 patients (85%) signifying that iron deposition in
t h e  p a n c r e a s  i s  c o m m o n  a n d  o f  v a r i a b l e  d e g r e e  s i n c e
childhood. Several studies reported that pancreatic
hemosiderosis results in abnormal MRI signal intensity,
and there is iron overload in the pancreas in up to 75-
100% of thalassemia major cases [11,13,25-28].
Table 2: Comparison between thalassemic patients with normal and abnormal glucose tolerance as regards clinical and 
laboratory data
Parameters Normal glucose 
tolerance(20)
Abnormal glucose 
tolerance (20)
t * P Sig.
Mean ± SD Mean ± SD
Age (yrs) 13.15 ± 3.56 14.85 ± 2.83 1.67 0.10 NS
Age at diagnosis (ms) 12.30 ± 18.63 7.20 ± 2.78 1.21 0.23 NS
Duration of chelation (yrs) 5.80 ± 3.07 5.73 ± 3.60 0.07 0.94 NS
Hb (gm/dl) 7.46 ± 1.24 7.61 ± 1.4 0.4 0.33 NS
FBG (mg/dl) 82.40 ± 7.16 138.75 ± 30.39 8.07 <0.0001 HS
PP (mg/dl) 120.80 ± 9.55 212.50 ± 47.58 8.45 <0.0001 HS
Median IQR Median IQR Z** P
Serum ferritin (ng/ml) 1704.5 1330-
2000
3251 3050-
4300
-3.03 0.002 HS
Abnormal glucose tolerance includes impaired glucose tolerance and diabetes;*Student t test **Mann-Whitney test; SD, standard deviation; 
IQR, interquartile range (25-75th percentile range); Hb, Hemoglobin; FBG, fasting blood glucose; PP, postprandial blood glucoseMatter et al. Diabetology & Metabolic Syndrome 2010, 2:23
http://www.dmsjournal.com/content/2/1/23
Page 5 of 9
Lower SIR of the pancreas in thalassemic patients with
abnormal glucose tolerance compared to non diabetic
thalassemic patients is in agreement with Papakonstanti-
nou et al. [13]. The SIR was correlated with endocrine
function as assessed by OGTT [13] but contradict Midiri
et al. [11]. In the study of Au et al. [25], the incidence of
abnormal T2* was 81% among both diabetic and non dia-
betic thalassemic patients. Midiri et al. [11] suggested
that markedly hypointense SI changes corresponding to
iron deposition is seen first followed by a hyperintense
pattern corresponding to a progressive fatty replacement
of the pancreatic parenchyma. This may explain why our
patients with IGT have slightly lower SIR of the pancreas
than patients with overt diabetes.
Moreover, the lack of significant difference between
diabetic and IGT patients in SIR of the liver and the pan-
creas may be explained that other causative factors for
diabetes such as genetic predisposition and immune
damage are unlikely to be reflected by MRI results [29].
Although established diabetic thalassemic patients sel-
dom recover normal glucose tolerance [30]; impaired glu-
cose tolerance is considered a reversible situation in beta-
thalassemia [2,5].
We observed positive correlation between both pancre-
atic and hepatic siderosis and age at diagnosis, however,
no correlation was revealed with age of patients. Au et al.
[25] reported increase in pancreatic T2* values with age.
Christoforidis [9] study showed a significant negative cor-
relation between MRI values in liver and age.
Negative correlation detected between serum ferritin
and SIR of the pancreas in our study is similar to Midiri et
al. [11] but contradict others [12,13]. Argyropoulou et al
[12] explained the lack of correlation between pancreatic
siderosis and serum ferritin by the fact that T2 relaxation
time depends on both siderosis and fatty infiltration of
the pancreas reported in their adult group of patients. In
addition, negative correlation between serum ferritin and
SIR of the liver in our studied patients was in concor-
dance with previous published data [12,13,15,31,32];
while no similar correlation was noted in other studies
[9,33].
Reduced SIR of the liver in thalassemic patients with
abnormal glucose tolerance compared to non diabetic
patients was in agreement with Papakonstantinou et al
[13]. This may denote the importance of hepatic iron
deposition in the development of insulin resistance [21].
Iron overload and liver damage were the most important
factors responsible for endocrine complications [4]. A
strong correlation between pancreatic and hepatic
siderosis was evident in our young studied patients. This
observation was concordant with Brewer et al [34] who
reported positive correlation between pancreatic R2* and
Table 3: Comparison between different groups of thalassemic patients and controls as regards signal intensity ratio of the 
liver and the pancreas.
SIR of Liver N Median IQR Χ2 value# P value
I) Controls 20 15.389 14.158-18.074 42.828 <.001*
II) Non diabetic(NGT) 20 .833 .646-.861
III) abnormal glucose tolerance 20 .489 .159-.769
I/II) z value** = -5.423 P value < .001*
I/III) z value** = -5.422 P value < .001*
II/III) z value** = -2.379 P value = .017*
SIR of pancreas N Median IQR Χ2 value# P value
I) Controls 20 18.036 16.165-20.183 38.384 <.001*
II) Non diabetic(NGT) 20 2.548 1.968-8.111
III) abnormal glucose tolerance 20 1.185 .833-1.519
I/II) z value** = -5.425 P value < .001*
I/III) z value** = -5.423 P value < .001*
II/III) z value** = -2.762 P value = .006*
#Kruskal Wallis test; **Mann Whitney test;*Significant; IQR, interquartile range (25-75th percentile range).Matter et al. Diabetology & Metabolic Syndrome 2010, 2:23
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hepatic iron content, although there was no similar corre-
lation in previous reports [13,25,28,35]; this discrepancy
may be attributed to pancreatic fatty replacement in their
adult patients altering SIR of the pancreas.
Preliminary results of this study showed significant
reduction in SIR of the pancreas in splenectomized thala-
ssemic patients compared to those with intact spleen.
This observation requires confirmation by further longi-
tudinal studies and may reflect decreased extrahepatic
iron buffering capacity in splenectomized patients [34]
with accelerated iron deposition in the pancreas. The
spleen acts as a store for nontoxic iron, thereby protect-
Table 4: Correlation between signal intensity ratio of the liver, the pancreas and different studied parameters.
Parameters SIR of liver SIR of pancreas
ρ value# P value ρ value# P value
Age .065 .620 .088 .504
Age at diagnosis .433 .005* .542 <.001*
Disease duration .228 .157 .279 .081
Transfusion 
frequency
-.162 .319 -.211 .192
Ferritin -.409 .009* -.532 <.001*
FBG -.449 <.001* -.416 <.001*
PP -.514 <.001* -.540 <.001*
AST -.363 .021* -.484 .002*
ALT -.242 .132 -.411 .009*
SIR of pancreas 0.93 <.001*
#Spearman rho correlation coefficient *Significant; N = 40; AST, aspartate aminotransferase; ALT, alanine aminotransferase; FBG, fasting 
blood glucose; PP, postprandial blood glucose; SIR, signal intensity ratio
Figure 1 T2*-weighted GRE image of (A) normal subject and (B) β-
thalassemia major patient with adequate chelation: (A) T2*-
weighted GRE image (TR/TE/FA 120/15/20) of 18 yr-old normal male 
subject with normal signal intensity in the liver and the pancreas. (B) 
T2*-weighted GRE image (TR/TE/FA 120/15/20) of 13 yr-old male with 
β-thalassemia major with adequate chelation showing normal signal 
intensity in the liver and the pancreas (TR, repetition time; TE, echo 
time; FA, flip angle).
                                    
 
 
 
 AAA   B  
Figure 2 T2*-weighted GRE image of (A) splenectomized and (B) 
non splenectomized diabetic β-thalassemia major patients: (A) 
T2*-weighted GRE image (TR/TE/FA 120/15/20) of 12 yr-old female 
splenectomized β-thalassemia major with newly diagnosed diabetes 
showing low-signal intensity in the liver and the pancreas suggesting 
severe iron overload. (B) T2*-weighted GRE image (TR/TE/FA 120/15/
20) of 16 yr-old female non splenectomized diabetic β-thalassemia 
major patient showing low-signal intensity in the liver and the spleen 
and normal signal intensity in the pancreas (TR, repetition time; TE, 
echo time; FA, flip angle).
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ing the rest of the body from this iron [36]. Thus, splenec-
tomized beta thalassemia major patients should be
strictly monitored for pancreatic iron overload by MRI to
avoid pancreatic dysfunction.
The present study advantages were inclusion of
younger patients and performance of examinations at a
single center. Study limitation included the lack of histo-
logical confirmation to verify the pancreatic MRI find-
ings, and the over representation of poorly chelated
patients which is common finding in developing coun-
tries. However, it is likely that advances in MRI tech-
niques in iron assessment and chelation therapy will
impact on future diabetic risk in thalassemia.
Conclusions
Pancreatic siderosis could be detected by T2*-weighted
gradient-echo MRI in young thalassemic patients, and
was more evident in patients with abnormal glucose tol-
erance. After splenectomy, iron deposition may be accel-
erated in the pancreas. We recommend intensive
Figure 3 Box and Whisker plot of signal intensity ratio of the pancreas (A), and the liver (B) of controls, thalassemic patients with normal 
and abnormal glucose tolerance. The lines in the box represent the median, the boxes are the 25-75th percentile range, and the whiskers are the 
10-90th percentile range.
 
B   A
Table 5: Comparison between non splenectomized and splenectomized thalassemic patients.
Parameters non splenectomized (8) Splenectomized (32) t* P Sig.
Mean ± SD Mean ± SD
Age (yrs) 12.63 ± 3.07 14.34 ± 3.30 1.34 0.19 NS
Duration of disease 
(yrs)
11.47 ± 3.65 13.50 ± 3.12 1.60 0.12 NS
Serum ferritin (mg/dl) 2374.63 ± 1183.90 2823.22 ± 1346.84 0.86 0.39 NS
Frequency of Blood 
Transfusion (wk)
3.13 ± 0.64 3.19 ± 0.69 0.23 0.82 NS
Median IQR Median IQR Z** P Sig.
SIR of liver 0.679 0.451-0.967 0.707 0.273-0.857 -.135 0.89 NS
SIR of pancreas 2.95 2.047-15.562 1.743 1.014-3.211 -2.03 .042 S
*Student t test **Mann-Whitney test; SD, standard deviation; IQR, interquartile range; SIR, signal intensity ratioMatter et al. Diabetology & Metabolic Syndrome 2010, 2:23
http://www.dmsjournal.com/content/2/1/23
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chelation regimen to patients with IGT and NGT with
reduced pancreatic SIR with strict follow up by MRI to
assess improvement of pancreatic siderosis with reduc-
tion in markers of iron overload.
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